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A novel radioﬂuorinated derivative of bombesin, 18F-AmBF3-MJ9, was synthesized and evaluated for its
potential to image prostate cancer by targeting the gastrin releasing peptide receptor (GRPR). AmBF3-
MJ9 was prepared from an ammoniomethyl-triﬂuoroborate (AmBF3) conjugated alkyne 2 and azi-
doacetyl-MJ9 via a copper-catalyzed click reaction, and had good binding afﬁnity for GRPR
(Ki = 0.5 ± 0.1 nM). The
18F-labeling was performed via a facile one-step 18F–19F isotope exchange reac-
tion, and 18F-AmBF3-MJ9 was obtained in 23 ± 5% (n = 3) radiochemical yield in 25 min with >99% radio-
chemical purity and 100 ± 32 GBq/lmol speciﬁc activity. 18F-AmBF3-MJ9 was stable in mouse plasma,
and was partially (22–30%) internalized after binding to GRPR. Positron emission tomography (PET)
imaging and biodistribution studies in mice showed fast renal excretion and good uptake of
18F-AmBF3-MJ9 by GRPR-expressing pancreas and PC-3 prostate cancer xenografts. Tumor uptake was
1.37 ± 0.25%ID/g at 1 h, and 2.20 ± 0.13%ID/g at 2 h post-injection (p.i.) with low background uptake
and excellent tumor visualization (tumor-to-muscle ratios of 75.4 ± 5.5). These data suggest that
18F-AmBF3-MJ9 is a promising PET tracer for imaging GRPR-expressing prostate cancers.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Radiolabeled bombesin (BBN) analogs that bind to gastrin
releasing peptide receptors (GRPR) have generated great interest
as cancer imaging probes due to overexpression of GRPR in several
cancers such as prostate, breast, lung and gastrointestinal can-
cers.1–6 Prostate cancer, in particular, has attracted most of the
attention as GRPR was reported to be overexpressed in 100% of
malignant lesions but not in the surrounding normal prostate
tissues.3
A variety of BBN analogs, including both agonists and antago-
nists, have been radiolabeled and evaluated for GRPR-targeted pros-
tate cancer imaging and therapy.7–15 Recent studies suggested that
radiolabeled BBN antagonists may have higher tumor uptake in
comparison to agonists, despite their low internalization rate.16
Among BBN antagonists, the potent RM26 (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2) has beenwidely derivatized for radiolabeling
with 64Cu/68Ga and 111In for imagingGRPR-expressing prostate can-
cer with positron emission tomography (PET) and single photon
emission computed tomography (SPECT), respectively.17–19 Recent
successful detection of GRPR-expressing prostate cancer in clinical
studies using RM26 derivatives (68Ga-BAY86-754820 and 64Cu-CB-
TE2A-AR0621) further demonstrated the potential usefulness of
radiolabeled GRPR antagonists for prostate cancer imaging.
Among commercially available imaging radioisotopes, 18F is the
most widely used for clinical PET imaging because of its ideal
nuclear properties including high positron branching fraction
(97%), low positron energy (0.64 MeV), and a suitable physical
half-life of 109.7 min.22 Due to the popularity of 18F-labeled
2-ﬂuorodeoxyglucose for cancer imaging, 18F is available daily in
multi-Curie quantities from most of medical cyclotron facilities.
This facile and on-demand production underscores the importance
of developing 18F-labeled BBN-based PET probes for a more efﬁ-
cient application in clinic for prostate cancer imaging.
Previously we reported a facile one-step 18F-labeling approach
via 18F-19F isotope exchange reaction on an ammoniomethyl-
triﬂuoroborate (AmBF3) moiety23 that could be conjugated to a
number of peptides and other bioconjugates. To explore the
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labeled tracers, we report the synthesis and biological evaluation
of a novel GRPR antagonist 18F-AmBF3-MJ9 (Scheme 1) for prostate
cancer imaging.
2. Materials and methods
2.1. Chemicals and instrumentation
N-Propargyl-N,N-dimethyl-ammoniomethyl boronylpinacolate
1 was prepared according to the previously reported procedures.23
All other chemicals and solvents were obtained from commercial
sources, and used without further puriﬁcation. [125I-Tyr4]-
Bombesin (81.4 TBq/mmol) was purchased from Perkin Elmer
(Waltham, MA). Peptide sequence of MJ9 was synthesized using
an AAPPTEC (Louisville, KY) Endeavor 90 peptide synthesizer.
Mass analyses were performed using a Bruker (Billerica, MA)
Esquire-LC/MS system with ESI ion source. Puriﬁcation and quality
control of 18F-AmBF3-MJ9 were performed on an Agilent (Santa
Clara, CA) HPLC System equipped with a model 1200 quaternary
pump, a model 1200 UV absorbance detector, and a Bioscan
(Washington DC) NaI scintillation detector. The radio-detector
was connected to a Bioscan B-FC-1000 Flow-count system, and
the output from the Bioscan Flow-count system was fed into an
Agilent 35900E Interface which converted the analog signal to digi-
tal signal. The operation of the Agilent HPLC system was controlled
using the Agilent ChemStation software. The following gradients
were used for HPLC puriﬁcation and quality control. Method A:
Agilent Eclipse XDB-C18 5 lm 9.2  250 mm semi-prep column;
Solvent A: 0.1% TFA water; solvent B: MeCN; 0–15 min, 20–40%
B; 15–20 min, 40–20% B; ﬂow rate: 4.5 mL/min. Method B:
Agilent Eclipse XDB-C18 5 lm 9.2  250 mm semi-prep column;
Solvent A: 0.1% TFA water; solvent B: MeCN; 0–2 min, 5–20% B;
2–5 min, 20–30% B; 5–20 min, 30–50% B; 20–22 min, 50–5% B;
ﬂow rate: 3 mL/min. Method C: Phenomenex Jupiter 10 lm C18
4.6  250 mm analytical column; Solvent A: 0.1% TFA water; sol-
vent B: MeCN; 0–2 min, 5–5% B; 2–7 min, 5–20% B; 7–12 min,
20–100% B; 12–18 min, 100–100%; 18–20 min, 100–5% B; ﬂow
rate: 2 mL/min. 18F-ﬂuoride was produced by the 18O(p, n)18F reac-
tion using an Advanced Cyclotron Systems Inc. (Richmond, Canada)
TR19 cyclotron. 18F-ﬂuoride Trap & Release Columns were pur-
chased from ORTG Inc. (Oakdale, TN) and C18 light Sep-Pak
cartridges were obtained from Waters (Mississauga, Canada).
Radioactivity of 18F-AmBF3-MJ9 were measured using a Capintec
(Ramsey, NJ) CRC-25R/W dose calibrator, and the radioactivity
of mouse tissues collected from biodistribution studies were
counted using a Packard (Waltham, MA) Cobra II 5000 Series
auto-gamma counter. PET imaging experiments were conducted
using a Siemens (Malvern, PA) Inveon microPET/CT scanner.
2.2. Synthesis of AmBF3-MJ92.2.1. Synthesis of azidoacetyl-MJ9
The sequence of MJ9, 4-amino-1-carboxymethyl-piperidine-D-
Phe-Gln-Trp-Ala-Val-Gly-His-Statine-Leu-NH2, was ﬁrst constructed
on resin using the solid-phase approach as previously
described.24 Then, 2-azidoacetic acid (5 equiv) was coupled to
the N-terminus via in situ activation using HCTU/HOBT (5 equiv)
and DIPEA (10 equiv) in NMP. The peptide was cleaved and
de-protected from the resin by treatment with a TFA/water/triiso-
propylsilane/1,2-ethanedithiol/thioanisole/phenol (81.5:5:1:2.5:5:5)
cocktail for 4 h. After precipitated by the addition of cold ether,
the crude product was ﬁltered, dried, and puriﬁed by HPLC using
Method A. Azidoacetyl-MJ9 was obtained in 48% yield. MS (ESI)
calculated for M+: 1335.7; found: 1335.7.2.2.2. Synthesis of AmBF3-MJ9
N-Propargyl-N,N-dimethylammonio-methylboronylpinacolate
1 (5.0 mg, 22.3 lmol) was converted to the corresponding tri-
ﬂuoroborate (alkynyl-AmBF3 2) by treating with KHF2 (3 M, 30 lL
in water), HCl (4 M, 30 lL), deionized water (20 lL) and DMF
(60 lL) at 45 C for 2 h, and then quenched by NH4OH (28%,
10 lL). The crude reaction was directly used for click conjugation
to azidoacetyl-MJ9 without further puriﬁcation. A mixture of azi-
doacetyl-MJ9 (5.0 mg, 3.75 lmol), CuSO4 (1.0 M, 5.0 lL), sodium
ascorbate (1.0 M, 12.5 lL) and 5% NH4OH (MeCN/H2O = 1:1,
50 lL) was added, and the new mixture was warmed up to 45 C
for 2 h. Puriﬁcation was performed by HPLC using Method B to
obtain 2.5 mg (45% yield) of AmBF3-MJ9. MS (ESI) calculated for
M+: 1500.8; found: 1501.8 [M+H]+. For convenience and to ensure
reproducibility, the puriﬁed AmBF3-MJ9 was stored solvent-free as
a lyophilized powder which was dissolved in ethanol and aliquoted
in quantities of 110 lg (75 nmol) for future radiolabeling
experiments.
2.3. In vitro binding assay
Competition binding assays were performed using GRPR-
expressing human prostate cancer PC-3 cells. The cells were
cultured in Ham’s F-12 medium under a humidiﬁed atmosphere
with 5% CO2 at 37 C. The culture media was supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin,
and 100 lg/mL streptomycin. Cells were cultured in 24-well plates
at a density of 0.1 million cells per well and grown to 75%
conﬂuence. Two hours prior to the experiment, the cells were
washed with phosphate-buffered saline (PBS) and incubated with
RPMI 1640 containing 2 mg/mL BSA, 4.8 mg/mL HEPES, 1 U/mL
penicillin G and 1 lg/mL streptomycin. A ﬁnal concentration of
4.2 pM of [125I-Tyr4]Bombesin and 105–1012 M of AmBF3-MJ9
were added to wells (triplicate) containing the cells, and the
mixture was incubated under agitation at 37 C for 45 min. The
cells were then washed 3 times with ice-cold PBS, trypsinized
and the cell-bound radioactivity was counted using a gamma
counter. The IC50 and Ki values of AmBF3-MJ9 were calculated by
non-linear curve ﬁtting using GraphPad Prism 6.01.
2.4. Radiolabeling
Just prior to radiosynthesis, AmBF3-MJ9 was resuspended in
aqueous pyridazine–HCl buffer (50 lL, pH = 2) in a polypropylene
Falcon tube. No carrier-added 18F-ﬂuoride (37 GBq) was obtained
by bombardment of H218O with 18-MeV proton, followed by trap-
ping on an anion exchange resin (9 mg, QMA, chloride form) col-
umn. The 18F-ﬂuoride was eluted off with 100 lL isotonic saline
into the reaction tube containing AmBF3-MJ9 (75 nmol). The tube
was heated at 80 C for 20 min, and quenched with 5% NH4OH
(2 mL). The mixture was loaded onto a C18 light Sep-Pak cartridge,
and free 18F-ﬂuoride was removed by ﬂushing twice with 4 mL DI
water. The desired 18F-AmBF3-MJ9 was then eluted off the column
with 0.5 mL 1:1 ethanol/saline, and diluted with saline for plasma
stability, internalization, biodistribution and PET/CT imaging stud-
ies. A small sample was removed for quality control by HPLC using
Method C.
2.5. Metabolic stability in mouse plasma
18F-AmBF3-MJ9 (20 lL) was added to the mouse plasma
(500 lL) and the mixture was incubated at 37 C for 0, 1 and 2 h.
At the end of incubation at each time point, the reaction was
quenched by adding 70% MeCN (1 mL) to the plasma solution.
The quenched reactions were centrifuged for 20 min, and the
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Scheme 1. Synthesis of AmBF3-MJ9 and radiosynthesis of 18F-AmBF3-MJ9.
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lyzed by HPLC using Method C.
2.6. Internalization study
The experiments were performed in triplicates at 30, 60 and
90 min incubation at 37 C according to previously published pro-
cedures.25 Brieﬂy, PC-3 cells were plated in 6-well plates at a den-
sity of 0.8–1 million cells per well and incubated overnight. DMEM
containing 1% FBS was used as a culture medium. On the day of the
experiment, the cells were washed with PBS and 1 ml of culture
medium containing 2.5 pmol of 18F-AmBF3-MJ9 was added to each
well. In separate wells with the same setup, BAY86-7548 (to a ﬁnal
concentration of 1 lM) was added for the determination of non-
speciﬁc binding. After incubation at 37 C to the pre-determined
time point, the cells were washed twice with ice-cold PBS followed
by two acid washes (Glycine–HCl, pH 2.8) for 10 min on ice. To
measure the internalized activity, the cells were lysed with 1 M
NaOH, the solution was counted on a gamma counter.
2.7. Biodistribution study
The animal protocol used for the animal studies was approved
by the Institutional Animal Care Committee of the University of
British Columbia and all experiments were performed in compli-
ance with the Canadian Council on Animal Care Guidelines. 8–
10 weeks old male immunodeﬁcient NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ (NSG) were obtained from an in-house breeding colony at the
Animal Resource Centre of the BC Cancer Research Centre. Mice
were inoculated subcutaneously in the dorsal ﬂank with 5  106PC-3 cells prepared in sterilized PBS/matrigel mixture. The tumors
were allowed to grow for approximately 4 weeks to reach 5–7 mm
in diameter for in vivo experiments.
For biodistribution study, 0.37–0.74 MBq (0.1 mL) of
18F-AmBF3-MJ9 was injected via the caudal lateral tail vein while
mice were under brief isoﬂurane sedation. The radioactivity in
the syringe was measured before and after injection to
determine the total amount of administrated 18F-AmBF3-MJ9. To
conﬁrm the speciﬁc uptake of 18F-AmBF3-MJ9 in GRPR-expressing
tissues, 100 lg of BAY86-7548 was pre-injected 15 min prior to
the radiotracer as a blocking agent to an additional group of mice
weighing 25–30 g. Mice were euthanized at pre-determined time
points (30 min, 1 h and 2 h, n = 3 per group) by isoﬂurane anesthe-
sia followed by CO2 breathing. Tissues of interest were collected,
rinsed with PBS, blotted dry, weighted and counted in a gamma
counter. The gamma counter was cross-calibrated with the dose
calibrator using an 18F standard curve. The tissue weight, associat-
ed counts per minute and the calibration factor were used to
calculate the percentage injected dose per gram of tissue (%ID/g).
2.8. PET/CT imaging
Static (1 h and 2 h, n = 3 per group) PET/CT imaging was per-
formed using a Siemens Inveon microPET/CT scanner. The PC-3
tumor-bearing mice were brieﬂy sedated for i.v. injection of 18F-
AmBF3-MJ9 as described above, and then allowed to recover and
roam freely in their cages. For blocking study 100 lg of BAY86-
7548 was administered 15 min prior to the injection of the radio-
tracer. At the pre-determined time point, the mice were sedated
with 2% isoﬂurane inhalation and placed in the scanner. A baseline
Figure 1. A representative displacement curve of [125I-Tyr4]bombesin by AmBF3-
MJ9.
Figure 2. Radio-HPLC analysis of puriﬁed 18F-AmBF3-MJ9. Only one single peak was
observed on both radio- (upper) and UV–VIS (lower) chromatograms.
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using 60 kV X-rays at 500 lA, using 3 sequential bed position with
33% overlap and 220 degree continuous rotation. The mice were
kept warm by a heating pad during acquisition. A single static
emission scan was acquired for 15 min. The mice were euthanized
after termination of scans, and the organs harvested for biodistri-
bution. PET image data were reconstructed using the Inveon
Acquisition Workplace using two iterations of the ordered subset
expectation maximization algorithm followed by 18 iterations of
the maximum a posteriori algorithm, using a beta factor of 0.1.
3. Results
3.1. Synthesis of AmBF3-MJ9
The synthesis of AmBF3-MJ9 is illustrated in Scheme 1. The
AmBF3-conjugated alkyne 2 was prepared by treating N-propar-
gyl-N,N-dimethyl-ammoniomethyl boronylpinacolate 123 with
KHF2 and the crude mixture was used directly for subsequent cou-
pling to the azidoacetyl-MJ9 without further puriﬁcation.
Azidoacetyl-MJ9 was synthesized using solid-phase peptide syn-
thesis approach, and obtained after HPLC puriﬁcation in 48% yield.
The click coupling of alkyne 2 and azidoacetyl-MJ9 generated the
desired AmBF3-MJ9 in 45% yield.
3.2. In vitro binding assay
Competition binding assays were performed to determine the
binding afﬁnity of AmBF3-MJ9 for GRPR using GRPR-expressing
PC-3 prostate cancer cells and the radioligand [125I-Tyr4]bombesin.
A representative displacement curve of [125I-Tyr4]bombesin by
AmBF3-MJ9 is shown in Figure 1. The IC50 was calculated to be
0.6 ± 0.1 nM (n = 3) and the corresponding Ki was 0.5 ± 0.1 nM.
3.3. Radiochemistry
Starting with37.0 GBq of 18F-ﬂuoride,7.4 GBq of 18F-AmBF3-
MJ9 was reproducibly obtained within 25 min (23 ± 5%, n = 3).
Puriﬁed 18F-AmBF3-MJ9 was re-injected into HPLC for quality con-
trol. As shown in Figure 2, only one peak was observed on both
radio- and UV–VIS chromatograms. The radiochemical purity and
speciﬁc activity of 18F-AmBF3-MJ9 were >99% and 100 ± 32 GBq/
lmol, respectively.
3.4. Metabolic stability in mouse plasma
18F-AmBF3-MJ9 was incubated in mouse plasma for up to 2 h at
37 C, and analyzed by HPLC to assess its in vitro stability. As
shown in Figure 3, there was no detectable decomposition on radio
chromatogram for all the selected time points (0.5, 1 and 2 h).
3.5. Internalization study
An internalization assay was conducted using PC-3 cells to
assess if the binding of 18F-AmBF3-MJ9 to GRPR triggers the inter-
nalization of receptor. As shown in Figure 4, no signiﬁcant change
of the membrane-bound fraction was observed over time, and the
numbers were 5.48 ± 0.15%, 5.84 ± 0.12%, and 5.32 ± 0.20% at 30, 60
and 90 min, respectively. The internalized fraction was
2.37 ± 0.29% at 30 min and 1.54 ± 0.27% at 90 min.
3.6. Biodistribution and imaging studies
Biodistribution of 18F-AmBF3-MJ9 was assessed in NSG mice
bearing PC-3 tumor xenografts. As summarized in Table 1, higheraccumulation was observed in GRPR-expressing PC-3 tumor, pan-
creas, and intestine. The uptake values for PC-3 tumor, pancreas
and intestine were 2.77 ± 0.80, 8.04 ± 3.64 and 4.28 ± 5.02%ID/g
at 0.5 h; 1.47 ± 0.15, 4.16 ± 1.34 and 6.30 ± 3.24%ID/g at 1 h; and
2.20 ± 0.13, 4.75 ± 2.36 and 8.67 ± 11.5%ID/g at 2 h, respectively.
Pre-blocking with 100 lg of a potent GRPR antagonist BAY86-
754820 led to 90% reduction in intestinal and pancreatic uptake,
and 60% reduction of uptake in PC-3 tumor at 1 h p.i. Tumor-
to-background (blood, muscle, liver and kidney) ratios increased
signiﬁcantly over time, and the tumor-to-blood and tumor-to-
muscle ratios reached 16.00 ± 15.00 and 77.00 ± 7.00, respectively,
at 2 h p.i. The PET/CT images of 18F-AmBF3-MJ9 in PC-3 tumor-
bearing mice were consistent with post-mortem biodistribution
data (Table 1). As shown in Figure 5, low background uptake and
high tumor-to-background ratios of 18F-AmBF3-MJ9 were observed
at 1 h (Fig. 5A) and 2 h (Fig. 5B) p.i. Tumor to muscle ratios at 1 h
and 2 h based on imaging data (from regions-of-interest) were
20 ± 8.8 and 76 ± 28, respectively. The radioactivity was excreted
Figure 3. Radio-HPLC analysis of metabolic stability of 18F-AmBF3-MJ9 in mouse
plasma after 0.5 (A), 1 (B), and 2 h (C) incubation at 37 C.
Table 1
Biodistribution and tumor-to-background ratios of 18F-AmBF3-MJ9 in NSG mice
bearing PC-3 tumors
Tissues 0.5 h 1 h 1 h pre-
blocked
2 h
Blood 2.10 ± 0.94 0.57 ± 0.38 0.48 ± 0.27 0.32 ± 0.35
Fat 0.25 ± 0.11 0.07 ± 0.03 0.12 ± 0.07 0.05 ± 0.05
Seminal gland 0.33 ± 0.12 0.70 ± 1.05 0.12 ± 0.08 0.15 ± 0.23
Testis 0.42 ± 0.05 0.25 ± 0.15 0.25 ± 0.18 0.13 ± 0.15
Intestine 4.28 ± 5.02 6.30 ± 3.24 0.25 ± 0.14 8.67 ± 11.50
Spleen 1.08 ± 0.25 0.33 ± 0.13 0.32 ± 0.09 0.26 ± 0.09
Liver 2.63 ± 0.55 0.78 ± 0.12 1.05 ± 0.34 0.33 ± 0.07
Pancreas 8.04 ± 3.64 4.16 ± 1.34 0.42 ± 0.48 4.75 ± 2.36
Adrenal gland 1.16 ± 0.12 0.50 ± 0.32 0.21 ± 0.14 0.29 ± 0.10
Kidney 6.60 ± 0.97 2.43 ± 0.39 6.66 ± 4.71 1.46 ± 0.29
Lung 1.96 ± 0.89 0.96 ± 0.19 0.71 ± 0.27 0.40 ± 0.09
Heart 0.54 ± 0.09 0.13 ± 0.02 0.18 ± 0.08 0.06 ± 0.02
Tumor 2.77 ± 0.80 1.47 ± 0.15 0.54 ± 0.27 2.20 ± 0.13
Muscle 0.38 ± 0.01 0.07 ± 0.03 0.14 ± 0.06 0.03 ± 0.00
Bone 0.70 ± 0.01 0.28 ± 0.08 0.25 ± 0.19 0.18 ± 0.01
Brain 0.07 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.01 ± 0.01
Target-to nontarget ratios
Tumor-to-blood 1.50 ± 0.68 3.40 ± 2.00 1.20 ± 0.32 16.00 ± 15.00
Tumor-to-muscle 7.30 ± 2.10 27.00 ± 18.00 4.00 ± 0.21 77.00 ± 7.00
Tumor-to-liver 1.10 ± 0.31 1.90 ± 0.42 0.50 ± 0.12 6.80 ± 0.99
Tumor-to-kidney 0.42 ± 0.10 0.62 ± 0.19 0.09 ± 0.02 1.60 ± 0.22
Uptake data are presented as %ID/g of tissues.
Figure 4. Percentages of membrane-bound and internalized radioactivity after
incubating 18F-AmBF3-MJ9 with PC-3 cells for up to 90 min.
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(Fig. 5C) signiﬁcantly reduced tumor uptake, renal activity, and
tumor-to-background contrast at 1 h p.i. (unpaired t-tests;
p <0.05), while no signiﬁcant differences were noted in liver and
muscle uptake.4. Discussion
Development of radiolabeled BBN derivatives for imaging
GRPR-expressing cancers has been an active research area in nucle-
ar medicine since late 90s.26,27 However, the focus has gradually
shifted from labeling agonists with SPECT isotopes26,27 such as
99mTc and 111In to labeling antagonists with PET isotopes17–19,28,29
including 68Ga, 64Cu and 18F. The advantages of PET include higher
sensitivity and resolution compared to SPECT which leads to
improved image quality and the ability to detect smaller
lesions. In terms of pharmacological properties, it has recently
been demonstrated by Cescato et al.16 that radiolabeled GRPR
antagonists were superior to agonists for in vivo imaging.
Although PET imaging provides many advantages over SPECT
and while 18F is often the preferred PET isotope, labeling peptides
with 18F is not trivial, and often involves several lengthy reaction/
separation steps, resulting in low radiochemical yields and low
speciﬁc activities. To meet the challenge of peptide labeling,
McBride et al.30 introduced a novel strategy for labeling peptides
with 18F via the complexation of [Al18F]2+ in aqueous solution with
a polyaminocarboxylate chelator on the peptide. Such facile
strategy eliminates the tedious water drying step, and the ﬁnal
18F-labeled product could be simply puriﬁed by solid-phase
extraction using a C18 Sep-Pak cartridge. This approach was quick-
ly adopted for the preparation of 18F-labeled peptides including
GRPR-targeting RM26 derivatives Al18F-NOTA-P2-RM2628 and
Al18F-NODAGA-RM1.29
In this study, we introduced a novel GRPR-targeting peptide 18F-
AmBF3-MJ9 for PET imaging of prostate cancer. AmBF3-MJ9 was
designed for labeling via the 18F–19F isotope exchange reaction on
AmBF3 recently reported by Perrin et al.23,31 The AmBF3-conjugated
alkyne 2 was coupled to an RM26 derivative, azidoacetyl-MJ9, via
Cu-catalyzed 2+3 dipolar cycloaddition to yield AmBF3-MJ9. The
afﬁnity of the parent peptide (H-D-Phe-Gln-Trp-Ala-Val-Gly-His-
(3S,4S)AHMHA-Leu-NH2) was measured in rat pancreatic acini by
Llinares et al., and found to be 0.9 nM.32 As expected, AmBF3-MJ9
retained high binding afﬁnity (Ki = 0.5 ± 0.1 nM) to GRPR. The
modiﬁcation at the N-terminus of BBN derivatives has been shown
to be tolerable, and the resulting peptides generally exhibit high
binding afﬁnity to GRPR.3,12,19,21,25,28,29 Thus, we conclude that
the addition of an amino-triﬂuoroborate construct had limited
impact on binding afﬁnity.
18F labeling of AmBF3-MJ9 was performed via a one-step 18F-19F
isotope exchange reaction in aqueous solution resulting in an over-
all non-decay corrected radiochemical yield of 23 ± 5% (n = 3).
Similar to the NOTA-Al18F labeling, isotope exchange labeling elim-
inates tedious drying and HPLC puriﬁcation steps, and the ﬁnal 18F-
labeled products could be obtained in <30 min of overall reaction/
puriﬁcation time. Recently, the conditions for labeling peptides via
NOTA-[Al18F]2+ complexation have been optimized, and up to 97%
radiochemical yield could be obtained in the presence of 80% (v/v)
acetonitrile or ethanol.33,34 Nevertheless, for such radiolabeling the
ratio of Al3+, starting 18F-ﬂuoride and peptide precursor needs to be
taken into account to ensure high radiochemical yield. Despite a
lower radiochemical yield herein, isotope exchange offers a sim-
pler radiolabeling approach that does not require coordinated
ratios of multiple components.
18F-AmBF3-MJ9 was metabolically stable in mouse plasma after
2 h incubation at 37 C. This is consistent with high metabolic
Figure 5. Small-animal PET/CT images of 18F-AmBF3-MJ9 in PC-3 prostate tumor bearing mice at 1 h (A) and 2 h (B) p.i., and at 1 h p.i. with pre-injection of 100 lg of BAY86-
7548 (C). The unit of color bars is in %ID/g ranging from 0 to 3%ID/g. B: bladder, I: intestine, K: kidney, T: tumor.
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However, in vivo metabolism data would be useful before further
clinical translation. Internalization study showed that the fraction
(5.32–5.84%) of membrane bound 18F-AmBF3-MJ9 remained
relatively constant between 30 and 90 min incubation, indicating
its fast binding kinetics to GRPR. The internalized fraction accounts
for 30% of total cell-associated radioactivity at 30 min, and
gradually decreased to 22% at 90 min. The extent of internaliza-
tion (22–30%) of 18F-AmBF3-MJ9 is within similar range (14–35%)
of reported radiolabeled RM26 derivatives.18,19,28,35 Interestingly,
for reported 68Ga- and 111In-labeled RM26 derivatives,19 the per-
centages of internalized fraction increased over time indicating
the residualizing characteristics of 68Ga and 111In radiolabels after
being internalized into cells. In the case of 18F-AmBF3-MJ9, the
internalized fraction slightly decreased over time (2.37 ± 0.29% at
30 min to 1.54 ± 0.27% at 90 min).
In vivo biodistribution (Table 1) and imaging (Fig. 5) studies in
PC-3 tumor-bearing mice showed excellent tumor visualization
and higher tumor contrast ratios at later time points. As shown
in Table 1, tumor-to-blood, tumor-to-muscle, and tumor-to-liver
ratios increased from 1.50 to 16.00 (10-fold), 7.30 to 77.00 (10-
fold), and 1.10 to 6.80 (6-fold), respectively, from 0.5 to 2 h p.i.
Preblocking with BAY86-7548 signiﬁcantly reduced the uptake of
18F-AmBF3-MJ9 in GRPR-expressing PC-3 tumors, pancreas, and
intestine, conﬁrming the uptake in these tissues was GRPR-mediated.
Only minimal bone uptake (0.18 ± 0.01%ID/g) was observed
indicating that there was no signiﬁcant in vivo deﬂuorination of
18F-AmBF3-MJ9. At the earlier 30 min time point, tumor accumula-
tion was only slightly higher than activity in the blood, suggesting
a combination of non speciﬁc and receptor-mediated uptake. The
tumor–blood ratios consistently increased over time, and this sup-
ports progressive receptor mediated accumulation replacing the
non-speciﬁc uptake of earlier time points.
The absolute PC-3 tumor uptake value was lower with 18F-
AmBF3-MJ9 (2.20 ± 0.13%ID/g at 2 h p.i.) than the reported 18F-la-
beled RM26 derivatives, Al18F-NOTA-P2-RM2628 (5.53 ± 0.75%ID/g
at 3 h p.i.) and Al18F-NODAGA-RM129 (5.25 ± 0.84%ID/g at 2 h
p.i.). Although inferior to Al18F-NOTA-P2-RM26, the tumor-to-
background contrasts of 18F-AmBF3-MJ9 were similar to those of
Al18F-NODAGA-RM1. N-terminus modiﬁcations have been shown
to change the pharmacokinetics of bombesin derivatives.36
Higher absolute tumor uptake values have been observed withAl18F derivatives,28,29 which suggests that chelators might have a
beneﬁcial effect on tumor accumulation with bombesin deriva-
tives. It is also possible that charge properties, blood clearance
and differences in GRPR expression in PC3 cells across labs could
inﬂuence the results.
Most importantly, we demonstrated that reliable radiochemical
yields (20%) and high speciﬁc activity (100 GBq/lmol) of 18F-
AmBF3-MJ9 could be obtained starting with 37 GBq of 18F-ﬂuor-
ide. These numbers are consistent with the radiochemical yield
and speciﬁc activity of previously reported somatostatin receptor
targeting tracer, 18F-AmBF3-TATE.31 The ﬁnal radioactivity of 18F-
AmBF3-MJ9 was obtained in 7 GBq which is enough for multiple
doses, and could be potentially delivered for use at multiple sites
from a single production batch. Al18F-NOTA-P2-RM26 and Al18F-
NODAGA-RM1 were prepared starting with lower quantities (1–
4 GBq) of 18F-ﬂuoride. Other methods have also been used for
radioﬂuorination of bombesin derivatives, notably by using N-suc-
cinimidyl-4-18F-ﬂuorobenzoate, 3-cyano-4-18F-ﬂuoro-benzoyl
derivatives or ﬂuoropyridine prosthetic groups, with variable suc-
cess.37–40 All of these methods required one or two HPLC puriﬁca-
tion steps, with lengthy radiolabeling procedures. Considering the
widespread availability of 18F, and the straightforward labeling
technique using the 18F–19F isotope exchange reaction, 18F-
AmBF3-MJ9 is a promising probe for non-invasive imaging of
GRPR in humans. The in vivo data supports further studies on the
potential utility of this radiotracer for detecting prostate cancers
and other GRP receptor positive cancers in human subjects.
5. Conclusion
We synthesized 18F-AmBF3-MJ9 and evaluated its potential as a
GRPR-targeting PET tracer. 18F-AmBF3-MJ9 demonstrated excellent
GRPR binding afﬁnity, high plasma stability, and favorable pharma-
cokinetics. In addition, speciﬁc tumor targeting and excellent
tumor-to-background contrasts further suggest that 18F-AmBF3-
MJ9 is a promising radiotracer for GRPR-targeting imaging.
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